Featured Posts
National Review
Prescription Drugs Save Lives at a (Mostly) Reasonable Cost
Prescription drugs are an extraordinary lifesaving and life-enhancing technology, so integrated into our daily lives that, nowadays, we perhaps take them for granted. Headlines and…
News Release
FDA deserves credit for approval pancreatic cancer drug
The FDA on August 26 approved a new breakthrough drug to treat pancreatic cancer. CEI Senior Fellow and Economist Jeremy Nighohossian praised…
Blog
Fauci’s lasting legacy will be the damage he did to science and government
Anthony Fauci isn’t faring well in the court of public opinion. His recently divulged “diary” and subsequent July 29 appearance before the Senate Homeland…
Search Posts
Products
Fred Smith and Michael Jacobson discuss proposed legislation to fight obesity on CNBC Capital Report
BODY: GLORIA BORGER, co-host: And welcome back to CAPITAL REPORT. The FDA is looking for ways to combat the exploding rate of obesity in…
Study
Safety, risk and the precautionary principle: rethinking precautionary approaches to the regulation of transgenic plants
Full Document Available in PDF Ever since completion of the Cartagena Protocol on Biosafety in…
Citation
Government in Your Car
CEI General Counsel Sam Kazman discusses the unintended consequences of government mandates for auto manufacturers. CAFE fuel effciency standards result in smaller, lighter cars, which…
Comment
Response to Citizen Petition Requesting Certain Prescription Allergy Medication be OTC
Commenters believe that the FDCA, read as an integrated whole, generally leaves the determination whether prescription drug or OTC drug labeling should be proposed for…
Legal Brief
Memorandum Opinion in Association of Physicians and Surgeons vs US FDA
Comment
Comments Regarding the Constitutionality of FDA Treatment of Product Information
This request for comments represents a welcome departure from FDA’s prior treatment of First Amendment concerns in the context of product advertising, labeling, and promotions.